Advertisement
Home »

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.

May 22, 2023

ABOUT THE CONTRIBUTORS

  • Shengyuan Yu

    Chinese PLA General Hospital, Beijing, China.

    Byung-Kun Kim

    Nowon Eulji Medical Center, Seoul, South Korea.

    Aihong Guo

    Yan’an University Xianyang Hospital, Xianyang, China.

    Man-Ho Kim

    Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

    Mingjie Zhang

    Chinese PLA General Hospital, Beijing, China.

    Zhen Wang

    Changsha Central Hospital, Changsha, China.

    Jianguang Liu

    Wuhan Third Hospital, Wuhan, China.

    Heui-Soo Moon

    Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.

    Ge Tan

    The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

    Qian Yang

    Shaanxi Provincial Hospital, Xi’an, China.

    Donnie McGrath

    Biohaven Pharmaceuticals, New Haven, CT, USA.

    Michael Hanna

    Biohaven Pharmaceuticals, New Haven, CT, USA.

    David A Stock

    Biohaven Pharmaceuticals, New Haven, CT, USA.

    Yanfei Gao

    BioShin Limited, Shanghai, China.

    Robert Croop

    Biohaven Pharmaceuticals, New Haven, CT, USA.

    Zhihong Lu

    BioShin Limited, Shanghai, China. Electronic address: sarah.lu@pfizer.com.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement